Chimerix to Report Third Quarter 2020 Financial Results and Provide an Operational Update on November 5, 2020
October 29 2020 - 7:00AM
Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on
accelerating the development of medicines to treat cancer and other
serious diseases, today announced that it will host a live
conference call and audio webcast on Thursday, November 5, 2020 at
8:30 a.m. ET to report financial results for the third quarter
ended September 30, 2020, and to provide a business overview.
To access the live conference call, please dial (877) 354-4056
(domestic) or (678) 809-1043 (international) at least five minutes
prior to the start time, and refer to conference ID 6085937. A live
audio webcast of the call will also be available on the Investors’
section of the Company's website, www.chimerix.com. An archived
webcast will be available on the Chimerix website approximately two
hours after the event.
About Chimerix
Chimerix is a development-stage biopharmaceutical company
dedicated to accelerating the advancement of innovative medicines
that make a meaningful impact in the lives of patients living with
cancer and other serious diseases. Its two clinical-stage
development programs are dociparstat sodium (DSTAT) and
brincidofovir (BCV).
DSTAT is a potential first-in-class glycosaminoglycan compound
derived from porcine heparin that, compared to commercially
available forms of heparin, may be dosed at higher levels without
associated bleeding-related complications. DSTAT is being studied
in a Phase 2/3 trial to assess safety and efficacy in adults with
acute lung injury with underlying COVID-19. A Phase 3 trial
protocol to study DSTAT in acute myeloid leukemia has been agreed
to with the US Food and Drug Administration (FDA) and site
activation is expected in early 2021. BCV is an antiviral drug
candidate in development as a medical countermeasure for smallpox.
For further information, please visit the Chimerix website,
www.chimerix.com.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
that are subject to risks and uncertainties that could cause actual
results to differ materially from those projected. Factors and
risks that could cause actual results to differ materially from
those indicated in the forward-looking statements are set forth in
the Company's filings with the Securities and Exchange Commission.
These forward-looking statements represent the Company's judgment
as of the date of this release. The Company disclaims, however, any
intent or obligation to update these forward-looking
statements.
CONTACT:
Investor Relations:Michelle LaSpaluto919
972-7115ir@chimerix.comWill O’ConnorStern Investor
Relations212-362-1200will@sternir.com Media:David SchullRusso
Partners858-717-2310David.Schull@russopartnersllc.com
Chimerix (NASDAQ:CMRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Chimerix (NASDAQ:CMRX)
Historical Stock Chart
From Sep 2023 to Sep 2024